Famicord AG (V3V) is rebranding its Contract Development and Manufacturing subsidiary, Famicord Cell and Gene Manufacturing, to Bramble Bio. This strategic move reflects the company’s commitment to innovation and growth in the field of novel cell therapies. “A core element of Famicord’s vision is to enhance access to cell therapies; Bramble Bio provides development services […]